To determine the longevity of effector CTLs following tumor clearance in vivo, we cotransferred control and PTPN22-deficient cells to transgenic C57BL/6-Ubc-GFP recipient mice bearing high-affinity EL4-OVA s.c. lymphomas. Here, UBC is linked to neoplasm.